Results 61 to 70 of about 10,093 (182)

Longer Asthma Duration Is Associated With Elevated Non‐T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma

open access: yesAllergy, EarlyView.
Longer asthma duration is associated with increased airway non‐T2 inflammation and reduced airway and systemic T2 inflammation. Sputum CXCL9 is independently associated with duration and may predict a reduced poor response to anti‐IL‐4Rα therapy. Airway sampling and combined T2 and non‐T2 targeted strategies may be needed in long‐standing asthma. CXCL9,
Freda Yang   +298 more
wiley   +1 more source

Long-Term Omalizumab use in the Treatment of Exercise-Induced Anaphylaxis

open access: yesAllergy & Rhinology, 2017
Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed.
Mark R. Peterson D.O.   +1 more
doaj   +1 more source

The Airway Transcriptome in Type 2 Cytokine Biomarker‐High and ‐Low Severe Asthma

open access: yesAllergy, EarlyView.
This study distinguishes severe asthma–related airway transcriptomic changes from the effects of high‐dose ICS. Most dysregulated genes in severe asthma show concordance with corticosteroid responses. Corticosteroid‐resistant T2‐high asthma featured T2‐high and epithelial barrier gene upregulation, while T2‐low asthma featured Th1/IL‐17 signatures. ASM,
Jiashu Shen   +19 more
wiley   +1 more source

How to evaluate a patient's response to anti-IgE

open access: yesEuropean Respiratory Review, 2007
Omalizumab, an anti-immunoglobulin E antibody, is indicated in the European Union (EU) as add-on therapy for patients with severe persistent allergic asthma whose symptoms persist, despite receiving optimised treatment with high-dose inhaled ...
S. T. Holgate
doaj  

Differential Effects of Benralizumab and Mepolizumab on Pro‐Resolving Mediators

open access: yes
Allergy, EarlyView.
Jaime Bernaola   +14 more
wiley   +1 more source

Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test

open access: yesAllergy, EarlyView.
ABSTRACT Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC4, while cytokine production occurs over a longer timescale, contributing to downstream immune responses.
Jitesh Chauhan   +5 more
wiley   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

Therapeutic potential of a Bax inhibitor‐1/TMBIM6 antagonist (BIA) and its analogues in Aspergillus fumigatus‐induced asthma via dual targeting of AKT and epithelial‐derived inflammatory cytokines

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Aspergillus fumigatus (A. fumigatus) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling.
Young‐Jin Yu   +7 more
wiley   +1 more source

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database

open access: yesScientific Reports
Omalizumab is a biologic agent used in the management of allergic conditions, including asthma and urticaria. Although the efficacy of omalizumab has been well established, its safety profile is primarily derived from clinical trials with limited sample ...
Yongfu Song   +5 more
doaj   +1 more source

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

open access: yesCase Reports in Medicine, 2015
Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria.
Misbah Nasheela Ghazanfar   +1 more
doaj   +1 more source

Home - About - Disclaimer - Privacy